

GammaTile: Reshaping Brachytherapy


David Casper, MD • Joel Hayden, MD • Mayra Anthony, BS • Nick Matthees, MD • Raza Mushtaq, MD

From the Department of Diagnostic Radiology, Creighton University School of Medicine, 3100 N Central Ave, Phoenix, AZ 85012 (D.C.); Department of Neuroradiology, Barrow Neurological Institute, Phoenix, Ariz (J.H., N.M., R.M.); and College of Liberal Arts and Sciences, Arizona State University, Tempe, Ariz (M.A.). Received November 26, 2023; revision requested January 23, 2024; revision received January 29; accepted February 12. Address correspondence to D.C. (email: davidcasperresidency@gmail.com).

Authors declared no funding for this work.

Conflicts of interest are listed at the end of this article.

Radiology: Imaging Cancer 2024; 6(2):e230208 • <https://doi.org/10.1148/rycan.230208> • Content codes: **NR** **OI** • © RSNA, 2024



Preoperative and postoperative images in a 55-year-old female patient with *IDH*-wildtype glioblastoma. **(A)** Axial T2-weighted preoperative image and **(B)** T1-weighted postcontrast image demonstrate a large necrotic mass with surrounding T2-weighted fluid-attenuated inversion recovery hyperintense signal abnormality in the right parietal lobe with mass effect causing leftward midline shift. **(C)** Axial postoperative bone window CT scan and **(D)** axial T2-weighted image show evenly spaced radiation seeds (GammaTiles) outlining the resection cavity.

A 55-year-old female patient with *IDH*-wildtype right parietal glioblastoma underwent tumor resection with

subsequent GammaTile (GT Medical Technologies) placement for brachytherapy (Figure).

This copy is for personal use only. To order printed copies, contact reprints@rsna.org

Keywords

Radiation Therapy, Neuro-Oncology, MR-Imaging, CT, Radiation Therapy/Oncology, CNS, Brain/Brain Stem, Neoplasms-Primary

GammaTile is a brachytherapy platform consisting of four titanium encapsulated cesium-131 seeds evenly spaced within a resorbable collagen tile matrix approximately the size of a postage stamp ($2 \times 2 \times 0.4$ cm) (1,2). It was recently approved by the U.S. Food and Drug Administration to treat new and malignant recurrent brain tumors, regardless of their histologic type. GammaTile is surgically implanted at the time of maximal safe tumor resection, and the radiation is emitted over approximately 6 weeks, reaching a target depth of 5–8 mm (1).

Due to the unique resorbable collagen housing, GammaTile therapy results in fewer adverse effects compared with traditional brachytherapy. Nonhoused brachytherapy seeds are subject to nontarget radiation and supratherapeutic dosing of immediately adjacent tissue. The collagen housing creates a fixed distance between target parenchyma and the cesium-131 seeds, as well as a fixed interseed distance to optimize uniform dose delivery. The bioresorbable matrix maintains its shape for approximately four

half-lives, 3–4 months, adding structure to both the implant and resection cavity. This design approach suggests improved rates of radiation necrosis and nontarget radiation (3).

The increasing use of GammaTile requires radiologist familiarity for effective treatment-related communication. Complications and long-term appearances are not well documented, given its recent introduction. Continuous monitoring is crucial for understanding potential implant changes.

Disclosures of conflicts of interest: D.C. No relevant relationships. J.H. No relevant relationships. M.A. No relevant relationships. N.M. No relevant relationships. R.M. No relevant relationships.

References

1. Gessler DJ, Ferreira C, Dusenbery K, Chen CC. GammaTile[®]: Surgically targeted radiation therapy for glioblastomas. *Future Oncol* 2020;16(30):2445–2455.
2. Ekhaton C, Nwankwo I, Rak E, Homayoonfar A, Fonkem E, Rak R. GammaTile: Comprehensive Review of a Novel Radioactive Intraoperative Seed-Loading Device for the Treatment of Brain Tumors. *Cureus* 2022;14(10):e29970.
3. Odia Y, Gutierrez AN, Kotecha R. Surgically targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review. *Neuro Oncol* 2022;24(Suppl 6):S16–S24.